Total submissions: 10
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000011236 | SCV000628123 | pathogenic | Mucopolysaccharidosis, MPS-II | 2023-04-01 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 10490). This premature translational stop signal has been observed in individuals with mucopolysaccharidosis type II (PMID: 1639384, 7887413, 21829674, 24780617). This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Arg172*) in the IDS gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in IDS are known to be pathogenic (PMID: 8940265, 9875019). |
Department of Medical Genetics, |
RCV000011236 | SCV001480205 | pathogenic | Mucopolysaccharidosis, MPS-II | criteria provided, single submitter | clinical testing | ||
Genome- |
RCV000011236 | SCV002014478 | pathogenic | Mucopolysaccharidosis, MPS-II | 2021-09-05 | criteria provided, single submitter | clinical testing | |
Laboratorio de Genetica e Diagnostico Molecular, |
RCV000011236 | SCV002512754 | pathogenic | Mucopolysaccharidosis, MPS-II | 2021-07-13 | criteria provided, single submitter | clinical testing | ACMG classification criteria: PVS1 very strong, PS3 supporting, PS4 moderate, PM2 moderate |
Ambry Genetics | RCV002336081 | SCV002644813 | pathogenic | Inborn genetic diseases | 2014-07-18 | criteria provided, single submitter | clinical testing | The p.R172* pathogenic mutation (also known as c.514C>T and 638C>T), located in coding exon 5 of the IDS gene, results from a C to T substitution at nucleotide position 514. This changes the amino acid from an arginine to a stop codon within coding exon 5. This mutation was originally reported in a patient with a clinical diagnosis Hunter syndrome (Flomen RH et al. Genomics. 1992;13(3):543-550). In addition to the clinical data presented in the literature, since premature stop codons are typically deleterious in nature, this alteration is interpreted as a disease-causing mutation (ACMG Recommendations for Standards for Interpretation and Reporting of Sequence Variations. Revision 2007. Genet Med. 2008;10:294). |
Foundation for Research in Genetics and Endocrinology, |
RCV000011236 | SCV002822851 | pathogenic | Mucopolysaccharidosis, MPS-II | 2023-01-16 | criteria provided, single submitter | clinical testing | A Hemizygous missense variation in exon 5 of the IDS gene that results in the termination of amino acid chain at codon 172 was detected. The observed variant c.514C>T (p.Arg172Ter) has not been reported in the 1000 genomes and gnomAD databases. The in silico prediction of the variant are possibly damaging by CADD and MutationTaster2. In summary, the variant meets our criteria to be classified as pathogenic. |
Gene |
RCV002512967 | SCV003194806 | pathogenic | not provided | 2023-01-18 | criteria provided, single submitter | clinical testing | Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss of function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 35144014, 25525159, 33676511, 21829674, 7887413, 9875019, 1639384, 30639582, 28077157) |
Laboratory of Diagnosis and Therapy of Lysosomal Disorders, |
RCV000011236 | SCV005089115 | pathogenic | Mucopolysaccharidosis, MPS-II | 2024-06-07 | criteria provided, single submitter | literature only | Null variant (PVS1_VeryStrong), Prevalence of the variant significantly increased in affected individuals compared with controls (PS4_Strong), Absent from controls (or at low frequency) in gnomAD database (PM2_Moderate), Patient’s phenotype or family history highly specific for the disease (PP4_Moderate) |
OMIM | RCV000011236 | SCV000031463 | pathogenic | Mucopolysaccharidosis, MPS-II | 1992-07-01 | no assertion criteria provided | literature only | |
Pediatrics, |
RCV000011236 | SCV001573781 | affects | Mucopolysaccharidosis, MPS-II | 2014-04-04 | no assertion criteria provided | research | The change c.514C>T (p.R172*) was found to be a nonsense variant, where the basic polar amino acid Arginine at 172 position was substituted by stop codon leading to early truncation of the peptide. It was found in the hemizygous condition in two non-familial patients with sever MPS-II phenotype. The patients hails from the Delhi and Bihar, India. |